Skip to content
Middletown Life
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA
August 6, 2026
Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution
June 30, 2026
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results
June 16, 2026
Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering
April 24, 2026
Sonoma Pharmaceuticals Announces Launch of New Dermatology Product Line under Person & Covey’s Aquanil Brand for Sensitive Skin
March 18, 2026
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results
February 13, 2026